Currently untreated adult women , ages 18 to 65years , with a primary psychiatric diagnosis of PTSD of at least 3months ' duration , are being enrolled in a parallel-group , double-blind , placebo-controlled , randomized clinical trial evaluating the efficacy and safety of GSK561679 , a novel CRHR1 receptor antagonist .